
    
      The investigators will evaluate the renal and neurohumoral effects of dual receptor (NPR-A
      and NPR-B) activation with CD-NP. This is a clinically relevant patient population who is at
      increased risk of developing diuretic resistance during the treatment of HF exacerbations.
    
  